Published in Nucleic Acids Res on March 28, 2007
A cell-permeable dominant-negative survivin protein induces apoptosis and sensitizes prostate cancer cells to TNF-α therapy. Cancer Cell Int (2010) 1.55
Suppression of survivin promoter activity by YM155 involves disruption of Sp1-DNA interaction in the survivin core promoter. Int J Biochem Mol Biol (2012) 1.08
A novel small molecule FL118 that selectively inhibits survivin, Mcl-1, XIAP and cIAP2 in a p53-independent manner, shows superior antitumor activity. PLoS One (2012) 1.05
Generation of a novel transgenic mouse model for bioluminescent monitoring of survivin gene activity in vivo at various pathophysiological processes: survivin expression overlaps with stem cell markers. Am J Pathol (2010) 0.93
An intravenous (i.v.) route-compatible formulation of FL118, a survivin, Mcl-1, XIAP, and cIAP2 selective inhibitor, improves FL118 antitumor efficacy and therapeutic index (TI). Am J Transl Res (2013) 0.87
Transcriptional inhibition of p21WAF1/CIP1 gene (CDKN1) expression by survivin is at least partially p53-dependent: evidence for survivin acting as a transcription factor or co-factor. Biochem Biophys Res Commun (2012) 0.87
Enhancing effectiveness of the MDR-sensitive compound T138067 using advanced treatment with negative modulators of the drug-resistant protein survivin. Am J Transl Res (2009) 0.87
Synergistic effect of allyl isothiocyanate (AITC) on cisplatin efficacy in vitro and in vivo. Am J Cancer Res (2015) 0.79
Functional studies of ssDNA binding ability of MarR family protein TcaR from Staphylococcus epidermidis. PLoS One (2012) 0.77
IAP family proteins--suppressors of apoptosis. Genes Dev (1999) 9.96
Control of apoptosis and mitotic spindle checkpoint by survivin. Nature (1998) 8.60
IAP proteins: blocking the road to death's door. Nat Rev Mol Cell Biol (2002) 7.23
Gfi-1 restricts proliferation and preserves functional integrity of haematopoietic stem cells. Nature (2004) 4.68
Survivin, versatile modulation of cell division and apoptosis in cancer. Oncogene (2003) 4.52
The inhibitors of apoptosis: there is more to life than Bcl2. Oncogene (2003) 2.71
Transcription factor Gfi1 regulates self-renewal and engraftment of hematopoietic stem cells. EMBO J (2004) 2.57
Survivin study: what is the next wave? J Cell Physiol (2003) 2.50
Transcriptional analysis of human survivin gene expression. Biochem J (1999) 2.39
Induction of survivin expression by taxol (paclitaxel) is an early event, which is independent of taxol-mediated G2/M arrest. J Biol Chem (2004) 1.73
Role of survivin and its splice variants in tumorigenesis. Br J Cancer (2005) 1.66
Survivin study: an update of "what is the next wave"? J Cell Physiol (2006) 1.63
Assignment of DNA binding sites for 4',6-diamidine-2-phenylindole and bisbenzimide (Hoechst 33258). A comparative footprinting study. Biochim Biophys Acta (1988) 1.60
Targets of the transcriptional repressor oncoprotein Gfi-1. Proc Natl Acad Sci U S A (2003) 1.49
Syntenin is overexpressed and promotes cell migration in metastatic human breast and gastric cancer cell lines. Oncogene (2002) 1.31
Molecular mechanism of inhibition of survivin transcription by the GC-rich sequence-selective DNA binding antitumor agent, hedamycin: evidence of survivin down-regulation associated with drug sensitivity. J Biol Chem (2005) 1.27
The zinc finger transcription factor Growth factor independence 1 (Gfi1). Int J Biochem Cell Biol (2005) 1.22
Silencing of antiapoptotic survivin gene by multiple approaches of RNA interference technology. Biotechniques (2004) 1.21
Prostate-derived Ets transcription factor (PDEF) downregulates survivin expression and inhibits breast cancer cell growth in vitro and xenograft tumor formation in vivo. Breast Cancer Res Treat (2006) 1.20
Differential regulation of survivin expression and apoptosis by vitamin D3 compounds in two isogenic MCF-7 breast cancer cell sublines. Oncogene (2005) 1.12
Differential expression of survivin-2B and survivin-DeltaEx3 is inversely associated with disease relapse and patient survival in non-small-cell lung cancer (NSCLC). Lung Cancer (2005) 1.10
Transcriptional and post-transcriptional controls of survivin in cancer cells: novel approaches for cancer treatment. J Exp Clin Cancer Res (2006) 1.09
Characterization of the 12C4 survivin monoclonal antibody and insight into the expression of survivin in human adult tissues. Histopathology (2006) 0.94
Hoechst 33342 induces apoptosis and alters tata box binding protein/DNA complexes in nuclei from BC3H-1 myocytes. Biochem Biophys Res Commun (1998) 0.87
Hoechst 33342-induced apoptosis is associated with intracellular accumulation of E2F-1 protein in BC3H-1 myocytes and HL-60 cells. Arch Pathol Lab Med (2001) 0.83
The fragile site (17)(p12): induction by AT-specific DNA-ligands and population cytogenetics. Hum Genet (1987) 0.79
In vivo tumor targeting and spectroscopic detection with surface-enhanced Raman nanoparticle tags. Nat Biotechnol (2007) 7.33
Polony multiplex analysis of gene expression (PMAGE) in mouse hypertrophic cardiomyopathy. Science (2007) 5.19
dbRIP: a highly integrated database of retrotransposon insertion polymorphisms in humans. Hum Mutat (2006) 4.23
In vivo molecular and cellular imaging with quantum dots. Curr Opin Biotechnol (2005) 3.92
In vivo magnetic enrichment and multiplex photoacoustic detection of circulating tumour cells. Nat Nanotechnol (2009) 3.21
Human genomic deletions mediated by recombination between Alu elements. Am J Hum Genet (2006) 3.15
Fluctuation analysis CalculatOR: a web tool for the determination of mutation rate using Luria-Delbruck fluctuation analysis. Bioinformatics (2009) 3.05
Abnormal calcium handling properties underlie familial hypertrophic cardiomyopathy pathology in patient-specific induced pluripotent stem cells. Cell Stem Cell (2013) 2.33
Exploring long-term protection of normal human fibroblasts and epithelial cells from chemotherapy in cell culture. Oncotarget (2011) 2.28
Application of nanotechnology in cancer therapy and imaging. CA Cancer J Clin (2008) 2.15
Identification of molecular pathway aberrations in uterine serous carcinoma by genome-wide analyses. J Natl Cancer Inst (2012) 2.09
Fat deposition in dilated cardiomyopathy assessed by CMR. JACC Cardiovasc Imaging (2013) 2.00
Genome editing of human embryonic stem cells and induced pluripotent stem cells with zinc finger nucleases for cellular imaging. Circ Res (2012) 1.84
Cross-talk between epidermal growth factor receptor and hypoxia-inducible factor-1alpha signal pathways increases resistance to apoptosis by up-regulating survivin gene expression. J Biol Chem (2006) 1.83
Human prx1 gene is a target of Nrf2 and is up-regulated by hypoxia/reoxygenation: implication to tumor biology. Cancer Res (2007) 1.80
Prevalence of idiopathic hypertrophic cardiomyopathy in China: a population-based echocardiographic analysis of 8080 adults. Am J Med (2004) 1.79
Alu retrotransposition-mediated deletion. J Mol Biol (2005) 1.79
Image-guided tumor ablation: standardization of terminology and reporting criteria--a 10-year update. Radiology (2014) 1.78
Induction of survivin expression by taxol (paclitaxel) is an early event, which is independent of taxol-mediated G2/M arrest. J Biol Chem (2004) 1.73
Genomic rearrangements by LINE-1 insertion-mediated deletion in the human and chimpanzee lineages. Nucleic Acids Res (2005) 1.73
Ras alters epithelial-mesenchymal transition in response to TGFbeta by reducing actin fibers and cell-matrix adhesion. Cell Cycle (2009) 1.70
Whole genome computational comparative genomics: A fruitful approach for ascertaining Alu insertion polymorphisms. Gene (2006) 1.68
Organ distribution of severe acute respiratory syndrome (SARS) associated coronavirus (SARS-CoV) in SARS patients: implications for pathogenesis and virus transmission pathways. J Pathol (2004) 1.62
Development of multifunctional nanoparticles for targeted drug delivery and noninvasive imaging of therapeutic effect. Curr Drug Discov Technol (2009) 1.60
Alu recombination-mediated structural deletions in the chimpanzee genome. PLoS Genet (2007) 1.59
Control of mammalian cochlear amplification by chloride anions. J Neurosci (2006) 1.59
PI3K/PTEN/AKT signaling regulates prostate tumor angiogenesis. Cell Signal (2007) 1.58
Phase Ⅰ clinical study of combination therapy with microwave ablation and cellular immunotherapy in hepatocellular carcinoma. Cancer Biol Ther (2011) 1.57
Mitochondrial stress engages E2F1 apoptotic signaling to cause deafness. Cell (2012) 1.56
Ru2 and Ru encode mouse orthologs of the genes mutated in human Hermansky-Pudlak syndrome types 5 and 6. Nat Genet (2003) 1.54
Screening drug-induced arrhythmia [corrected] using human induced pluripotent stem cell-derived cardiomyocytes and low-impedance microelectrode arrays. Circulation (2013) 1.54
Prostate-derived Ets transcription factor as a favorable prognostic marker in ovarian cancer patients. Int J Cancer (2008) 1.52
Real-time detection of gene expression in cancer cells using molecular beacon imaging: new strategies for cancer research. Cancer Res (2005) 1.49
Tissue specific differentially methylated regions (TDMR): Changes in DNA methylation during development. Genomics (2008) 1.42
Estrogen receptor alpha inhibits p53-mediated transcriptional repression: implications for the regulation of apoptosis. Cancer Res (2007) 1.42
Carbon nanotube based 3-D matrix for enabling three-dimensional nano-magneto-electronics [corrected]. PLoS One (2012) 1.40
Fibromuscular dysplasia affecting a two-branched renal artery in a patient with a solitary kidney: case presentation. Clin Cardiol (2013) 1.38
Quantum dots and multifunctional nanoparticles: new contrast agents for tumor imaging. Nanomedicine (Lond) (2006) 1.32
Real-time contrast-enhanced ultrasound in diagnosing of focal spleen lesions. Eur J Radiol (2011) 1.31
KLF5 Interacts with p53 in regulating survivin expression in acute lymphoblastic leukemia. J Biol Chem (2006) 1.30
Quantification of the heterogeneity in breast cancer cell lines using whole-cell impedance spectroscopy. Clin Cancer Res (2007) 1.29
Survivin repression by p53, Rb and E2F2 in normal human melanocytes. Carcinogenesis (2007) 1.29
Theranostic nanoparticles with controlled release of gemcitabine for targeted therapy and MRI of pancreatic cancer. ACS Nano (2013) 1.28
Molecular mechanism of inhibition of survivin transcription by the GC-rich sequence-selective DNA binding antitumor agent, hedamycin: evidence of survivin down-regulation associated with drug sensitivity. J Biol Chem (2005) 1.27
Interleukin-31 and oncostatin-M mediate distinct signaling reactions and response patterns in lung epithelial cells. J Biol Chem (2006) 1.27
A comparison of microwave ablation and bipolar radiofrequency ablation both with an internally cooled probe: results in ex vivo and in vivo porcine livers. Eur J Radiol (2010) 1.27
VRK1 signaling pathway in the context of the proliferation phenotype in head and neck squamous cell carcinoma. Mol Cancer Res (2006) 1.26
Different evolutionary fates of recently integrated human and chimpanzee LINE-1 retrotransposons. Gene (2006) 1.26
DNA damage induces a novel p53-survivin signaling pathway regulating cell cycle and apoptosis in acute lymphoblastic leukemia cells. J Pharmacol Exp Ther (2002) 1.26
Reducing non-specific binding and uptake of nanoparticles and improving cell targeting with an antifouling PEO-b-PgammaMPS copolymer coating. Biomaterials (2010) 1.25
Identification and characterization of novel polymorphic LINE-1 insertions through comparison of two human genome sequence assemblies. Gene (2006) 1.24
Improving the magnetic resonance imaging contrast and detection methods with engineered magnetic nanoparticles. Theranostics (2012) 1.24
Externally controlled on-demand release of anti-HIV drug using magneto-electric nanoparticles as carriers. Nat Commun (2013) 1.23
Association of telomere length with authentic pluripotency of ES/iPS cells. Cell Res (2011) 1.22
Genomic identification and biochemical characterization of the mammalian polyamine oxidase involved in polyamine back-conversion. Biochem J (2003) 1.21
Silencing of antiapoptotic survivin gene by multiple approaches of RNA interference technology. Biotechniques (2004) 1.21
Prostate-derived Ets transcription factor (PDEF) downregulates survivin expression and inhibits breast cancer cell growth in vitro and xenograft tumor formation in vivo. Breast Cancer Res Treat (2006) 1.20
Percutaneous sonographically guided microwave coagulation therapy for hepatocellular carcinoma: results in 234 patients. AJR Am J Roentgenol (2003) 1.18
G-DOC: a systems medicine platform for personalized oncology. Neoplasia (2011) 1.18
Superantigens and streptococcal toxic shock syndrome. Emerg Infect Dis (2003) 1.17
Metagenomic insights into the fibrolytic microbiome in yak rumen. PLoS One (2012) 1.17
Prognostic factors and recurrence of small hepatocellular carcinoma after hepatic resection or microwave ablation: a retrospective study. J Gastrointest Surg (2007) 1.16
Cellular model of Warburg effect identifies tumor promoting function of UCP2 in breast cancer and its suppression by genipin. PLoS One (2011) 1.16
Mechanistic relationships between Drosophila fragile X mental retardation protein and metabotropic glutamate receptor A signaling. Mol Cell Neurosci (2008) 1.15
Antibody conjugated magnetic iron oxide nanoparticles for cancer cell separation in fresh whole blood. Biomaterials (2011) 1.14
Down-regulation of inhibitor of apoptosis proteins by deguelin selectively induces apoptosis in breast cancer cells. Mol Pharmacol (2006) 1.14
Imaging of urokinase-type plasminogen activator receptor expression using a 64Cu-labeled linear peptide antagonist by microPET. Clin Cancer Res (2008) 1.13
Induction of cell cycle arrest by human T-cell lymphotropic virus type 1 Tax in hematopoietic progenitor (CD34+) cells: modulation of p21cip1/waf1 and p27kip1 expression. J Virol (2005) 1.13
Differential regulation of survivin expression and apoptosis by vitamin D3 compounds in two isogenic MCF-7 breast cancer cell sublines. Oncogene (2005) 1.12
Transcriptional targeting of tumors with a novel tumor-specific survivin promoter. Cancer Gene Ther (2004) 1.12
Blocking ion channel KCNN4 alleviates the symptoms of experimental autoimmune encephalomyelitis in mice. Eur J Immunol (2005) 1.10
The DREAM protein negatively regulates the NMDA receptor through interaction with the NR1 subunit. J Neurosci (2010) 1.10
Differential expression of survivin-2B and survivin-DeltaEx3 is inversely associated with disease relapse and patient survival in non-small-cell lung cancer (NSCLC). Lung Cancer (2005) 1.10
Up-regulation of peroxiredoxin 1 in lung cancer and its implication as a prognostic and therapeutic target. Clin Cancer Res (2008) 1.10
Pleiotrophin induces transdifferentiation of monocytes into functional endothelial cells. Arterioscler Thromb Vasc Biol (2006) 1.10
Induced pluripotent stem cells as a disease modeling and drug screening platform. J Cardiovasc Pharmacol (2012) 1.09
A global census of fission yeast deubiquitinating enzyme localization and interaction networks reveals distinct compartmentalization profiles and overlapping functions in endocytosis and polarity. PLoS Biol (2010) 1.08
Development of autoimmunity in IL-14alpha-transgenic mice. J Immunol (2006) 1.08
Expression profiling of archival renal tumors by quantitative PCR to validate prognostic markers. Biotechniques (2007) 1.08
Suppression of survivin promoter activity by YM155 involves disruption of Sp1-DNA interaction in the survivin core promoter. Int J Biochem Mol Biol (2012) 1.08
Cancer cell sensitivity to bortezomib is associated with survivin expression and p53 status but not cancer cell types. J Exp Clin Cancer Res (2010) 1.07
Restriction landmark genomic scanning (RLGS) spot identification by second generation virtual RLGS in multiple genomes with multiple enzyme combinations. BMC Genomics (2007) 1.07
Current and future clinical applications for optical imaging of cancer: from intraoperative surgical guidance to cancer screening. Semin Oncol (2011) 1.07
Prostate-derived Ets transcription factor (PDEF) is a potential prognostic marker in patients with prostate cancer. Prostate (2011) 1.06
Identification of allosteric PIF-pocket ligands for PDK1 using NMR-based fragment screening and 1H-15N TROSY experiments. Chem Biol Drug Des (2009) 1.05
Cytogenetic and cDNA microarray expression analysis of MCF10 human breast cancer progression cell lines. Cancer Res (2009) 1.05
A novel small molecule FL118 that selectively inhibits survivin, Mcl-1, XIAP and cIAP2 in a p53-independent manner, shows superior antitumor activity. PLoS One (2012) 1.05
A comparison of the aging and apoptotic transcriptome of Saccharomyces cerevisiae. FEMS Yeast Res (2005) 1.05
Neuronal loss of Drosophila NPC1a causes cholesterol aggregation and age-progressive neurodegeneration. J Neurosci (2008) 1.04
Resveratrol reduces the elevated level of MMP-9 induced by cerebral ischemia-reperfusion in mice. Life Sci (2006) 1.04
The mechanism of methylselenocysteine and docetaxel synergistic activity in prostate cancer cells. Mol Cancer Ther (2006) 1.04
A case of wedge resection of duodenum for massive gastrointestinal bleeding due to duodenal metastasis by renal cell carcinoma. World J Surg Oncol (2012) 1.03
T₁-weighted ultrashort echo time method for positive contrast imaging of magnetic nanoparticles and cancer cells bound with the targeted nanoparticles. J Magn Reson Imaging (2011) 1.03
Proteasomes and proteasome activator 200 kDa (PA200) accumulate on chromatin in response to ionizing radiation. Radiat Res (2007) 1.02